FDA removed 12 peptides from category 2 in 2026
on april 15, 2026, FDA cleared the way for BPC-157, GHK-Cu, TB-500, and nine others to move through the 503A process. it's the first real regulatory motion in years, but it's not the finish line. the PCAC meets july 23-24 to decide what happens next.
for educational purposes only. this article summarizes current regulatory activity and does not constitute legal or medical advice. compounding rules vary by state and the FDA process described here is still in progress. consult a licensed pharmacist or healthcare professional for decisions about peptide sourcing.
what actually happened on april 15
on april 15, 2026, FDA posted an update to its 503A Categories list -- the document that tells compounding pharmacies which bulk drug substances they can work with. twelve peptides were removed from category 2, effective april 22, 2026[1]. HHS Secretary Robert F. Kennedy Jr. announced the move publicly the same week, framing it as a win for compounding access and peptide research[2].
this is the first formal regulatory action on these substances since the february 2026 HHS signal that the administration wanted to re-examine peptide compounding policy. BioPharma Dive, STAT, and the Washington Post all covered the April filing within 24 hours[3][4][5].
the 12 peptides removed from category 2
- BPC-157 -- body protection compound, gut-derived peptide studied for tissue repair
- TB-500 -- synthetic fragment of thymosin beta-4, studied for recovery and wound healing
- GHK-Cu -- copper tripeptide, used topically and injectably for skin and connective tissue
- Epithalon -- tetrapeptide linked to telomerase activation in rodent studies
- MOTS-c -- mitochondrial-derived peptide studied for metabolic function and AMPK signaling
- DSIP -- delta sleep-inducing peptide, researched for sleep architecture
- Melanotan II -- synthetic melanocortin agonist used off-label for pigmentation
- KPV -- tripeptide derived from alpha-MSH, studied for anti-inflammatory effects
- LL-37 -- cathelicidin-derived antimicrobial peptide
- Semax -- ACTH-derived heptapeptide researched as a nootropic in russia
- Dihexa -- angiotensin IV analog studied in preclinical cognition models
- MK-677 (ibutamoren) -- non-peptide ghrelin mimetic grouped with the list in the docket
note that MK-677 is not technically a peptide -- it's a small-molecule growth-hormone secretagogue -- but it shows up on the same FDA docket as the 11 peptides above, which is why it's included here.
what "removed from category 2" doesn't mean
this is the part almost every social post gets wrong. FDA did not move these peptides to category 1. they didn't become legal for broad compounding on april 22. and they're not FDA-approved drugs. here is the actual regulatory ladder:
- category 1 -- bulk drug substances added to the 503A list. licensed pharmacies can compound them under prescription, subject to state rules. this is what advocates are asking for.
- category 2 -- bulk drug substances identified as raising significant safety risks in compounding. effectively off-limits for 503A pharmacies.
- category 3 -- bulk drug substances nominated for review but not yet evaluated.
the April 15 update moves these 12 substances out of category 2, but not automatically into category 1. each one still has to be reviewed by the Pharmacy Compounding Advisory Committee (PCAC), and then FDA has to issue a final rule adding it to the 503A bulks list[6]. until those two steps happen, the peptides sit in an intermediate status: no longer flagged as high-risk, but not yet explicitly approved for compounding either.
what happens on july 23-24
the PCAC will meet over two days at FDA headquarters in Silver Spring, MD to discuss whether these substances belong on the 503A bulks list[7].
- day 1 (july 23): BPC-157, KPV, TB-500, and MOTS-c.
- day 2 (july 24): the remaining substances.
FDA has opened docket FDA-2025-N-6895 for public comment, which remains open until july 22, 2026. a follow-up PCAC meeting is scheduled before the end of february 2027 to cover any substances not fully addressed in july[7].
PCAC votes are advisory, not binding -- but FDA typically follows them. the realistic window for final rulemaking that would formally add these peptides to category 1 is late 2026 through mid-2027.
who this actually affects
compounding pharmacies (503A and 503B)
503A pharmacies -- the ones that prepare patient-specific prescriptions -- are the group with the most direct stake. the april 22 category 2 removal gives them cover to start preparing operationally, but most will wait for PCAC recommendations and a final FDA rule before stocking these substances. 503B outsourcing facilities (the ones that make larger sterile batches for clinics) follow a stricter bulks list and are unlikely to touch these peptides before formal rulemaking is complete[8].
practitioners and clinics
functional-medicine clinics, wellness practices, and licensed prescribers have been operating in a gray zone for years. category 2 removal doesn't change what a physician can legally prescribe today, but it reduces the compliance risk of maintaining a relationship with a compounding pharmacy that stocks these substances. the bigger shift comes once FDA issues the final category 1 rule.
researchers and biohackers
if you're buying through non-pharmacy channels -- research-chemical vendors, overseas suppliers, grey-market resellers -- the April 15 update changes essentially nothing about your legal exposure today. federal law still doesn't authorize non-prescription retail sale of these peptides to consumers. the update does, however, make it more realistic that a licensed compounding pharmacy will be a legal option by late 2026 or 2027, which is a meaningful upgrade over the current sourcing landscape.
which of these we cover in depth
four of peptides academy's published mastery courses directly cover peptides on the list:
- BPC-157 -- full course covering chemistry, mechanism, clinical evidence, and safety.
- GHK-Cu -- multi-unit course on the copper peptide, including skin and wound-healing applications.
- Melanotan II -- mechanism, pigmentation pharmacology, and the distinction from Melanotan I.
- Semax -- ACTH-derived heptapeptide, cognitive and neurochemistry track including dosing and regulatory landscape.
our Melanotan I course covers a sibling peptide (afamelanotide) with overlapping MC1R biology. the TB-500 course is currently in draft and will launch after its content review completes.
peptide sourcing checksheet
once the PCAC vote lands in july, a lot of people are going to be evaluating compounding pharmacies for the first time. the checksheet below walks through the quality, licensing, and documentation questions you should have answers to before handing over a prescription. it's free and runs in your browser.
frequently asked questions
FDA removed 12 peptides from its 503A category 2 list, effective april 22, 2026. category 2 means a bulk drug substance may raise significant safety risks in compounding. removal from category 2 does not mean the peptides are automatically legal for compounding -- each one still has to be reviewed by the PCAC before it can be added to the 503A bulks list (category 1).
BPC-157, TB-500, GHK-Cu, epithalon, MOTS-c, DSIP, melanotan II, KPV, LL-37, semax, dihexa, and MK-677 (ibutamoren). MK-677 is technically a non-peptide ghrelin mimetic that has been grouped with the peptides list in the FDA docket.
the pharmacy compounding advisory committee meets july 23-24, 2026 at FDA headquarters in silver spring, MD. day 1 covers BPC-157, KPV, TB-500, and MOTS-c. day 2 covers the remaining substances. a follow-up meeting is expected before the end of february 2027. FDA has also opened docket FDA-2025-N-6895 for public comment, closing july 22, 2026.
not clearly. between the april 22 category 2 removal and a final FDA rule adding each substance to the 503A bulks list, these peptides sit in an intermediate status -- no longer flagged as high-risk by FDA, but not yet explicitly permitted either. most 503A pharmacies will wait for the PCAC recommendation and final FDA determination before stocking them. 503B outsourcing facilities follow a stricter list and are unlikely to touch these before final rulemaking.
no. FDA approval means a specific drug product completed phase 1-2-3 clinical trials and received marketing authorization for a defined indication. none of the 12 peptides on this list are FDA-approved. category 1 status -- if granted -- would allow licensed pharmacies to compound them under prescription, which is a different legal pathway than approval.
HHS secretary Robert F. Kennedy Jr. has publicly backed broader compounding access to these peptides. advocacy groups, compounding pharmacies, and functional-medicine practitioners have petitioned FDA for years, arguing that blanket category 2 treatment was overly restrictive for compounds with long community use and limited reported adverse events. FDA's april 15 action is the first formal regulatory movement in response.
yes -- four of our published mastery courses directly cover peptides on the list: BPC-157, GHK-Cu, melanotan II, and semax. our melanotan I course covers a sibling peptide with overlapping mechanism. the TB-500 course is currently in draft and not yet available.
wait for the PCAC recommendation before assuming broad compounding access. if sourcing from a compounding pharmacy, verify state licensing, request a certificate of analysis, confirm USP compounding standards are followed, and work with a licensed practitioner who can document medical necessity. the peptide sourcing checksheet above walks through the full quality review.
references
- U.S. Food and Drug Administration. "503A Categories Update." April 2026. fda.gov/media/94155/download.
- Washington Post. "FDA takes first step in possible reversal of ban on some peptides." April 15, 2026.
- BioPharma Dive. "FDA moves toward easing restrictions on certain peptides." April 15, 2026.
- STAT News. "FDA peptide advisers expected to support RFK Jr.'s legalization push." April 15, 2026.
- RAPS. "FDA considers adding a dozen peptides to its bulk drug compounding list." April 2026.
- U.S. FDA. "Evaluation of Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act." Guidance for Industry.
- Federal Register. "Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments -- Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List." Docket FDA-2025-N-6895, April 16, 2026.
- U.S. FDA. "Compounding and the FDA: Questions and Answers." Overview of 503A and 503B pathways.
- Sato M, et al. "Body Protection Compound-157 (BPC-157): Mechanisms of Action and Therapeutic Potential." Peptides. 2023;166:171182.
- Pickart L, Margolina A. "Regenerative and Protective Actions of the GHK-Cu Peptide." International Journal of Molecular Sciences. 2018;19(7):1987.